Strides Plans Re-Entry On Injectables
A non-compete agreement with Mylan ends in December
Executive Summary
Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.
You may also be interested in...
Strides Begins Biosimilar Filings With Teriparatide
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.
Strides Injectables Re-Entry Shifts Into High Gear
Strides Pharma Science, which has reported a strong second-quarter performance, said its reborn injectables business will “be full-blown” in several markets by December thanks to the expiry of a non-compete agreement with Mylan.
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?